TN2009000094A1 - Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors - Google Patents

Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Info

Publication number: TN2009000094A1
Authority: TN; Tunisia
Prior art keywords: leukemia; tyrosine kinase; abl tyrosine; cmin; bcr
Prior art date: 2006-09-22

Application number

TN2009000094A

Other languages

English (en)

Inventor

Insa Gathmann

Francois-Xavier Mahon

Stephane Picard

Yanfeng Wang

Mathieu Molimard

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-22

Filing date

2009-03-19

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-19 Application filed by Novartis Ag filed Critical Novartis Ag

2010-08-19 Publication of TN2009000094A1 publication Critical patent/TN2009000094A1/fr

Links

208000032839 leukemia Diseases 0.000 title abstract 4
229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
229960002411 imatinib Drugs 0.000 abstract 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
230000035945 sensitivity Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Ecology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TN2009000094A 2006-09-22 2009-03-19 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors TN2009000094A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US82662206P	2006-09-22	2006-09-22
US82827806P	2006-10-05	2006-10-05
PCT/US2007/078978 WO2008036792A2 (fr)	2006-09-22	2007-09-20	Procédé d'optimisation de traitement de la leucémie philadelphie positive avec des inhibiteurs de tyrosine kinase abl

Publications (1)

Publication Number	Publication Date
TN2009000094A1 true TN2009000094A1 (en)	2010-08-19

Family

ID=39092883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000094A TN2009000094A1 (en)	2006-09-22	2009-03-19	Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors

Country Status (25)

Country	Link
US (2)	US20090281113A1 (fr)
EP (2)	EP2068938B1 (fr)
JP (1)	JP5735742B2 (fr)
KR (1)	KR20090065512A (fr)
AT (1)	ATE495761T1 (fr)
AU (1)	AU2007299764B2 (fr)
BR (1)	BRPI0717099A2 (fr)
CA (1)	CA2662977A1 (fr)
CL (1)	CL2007002725A1 (fr)
CY (1)	CY1111356T1 (fr)
DE (1)	DE602007012122D1 (fr)
DK (1)	DK2068938T3 (fr)
HK (1)	HK1133194A1 (fr)
HR (1)	HRP20110250T1 (fr)
IL (1)	IL197296A (fr)
MA (1)	MA30786B1 (fr)
MX (1)	MX2009003082A (fr)
NO (1)	NO20091490L (fr)
NZ (1)	NZ575113A (fr)
PL (1)	PL2068938T3 (fr)
PT (1)	PT2068938E (fr)
TN (1)	TN2009000094A1 (fr)
TW (1)	TWI398251B (fr)
WO (1)	WO2008036792A2 (fr)
ZA (1)	ZA200901220B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101951910B (zh) *	2008-01-23	2013-07-17	诺瓦提斯公司	优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
EP2370078A1 (fr)	2008-12-01	2011-10-05	Novartis AG	Méthode d optimisation du traitement de la leucémie philadelphie positive avec du mésylate d imatinib
US20110046919A1 (en)	2009-03-02	2011-02-24	Juliesta Elaine Sylvester	Method for accurate measurement of enzyme activities
FR2943418A1 (fr) *	2009-03-17	2010-09-24	Centre Nat Rech Scient	Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
EP3072964A1 (fr) *	2013-11-22	2016-09-28	National Center For Child Health And Development	Nouveau gène chimère atf7ip-pdgfrb pour la leucémie lymphoblastique aiguë
CN108271374B (zh)	2015-07-07	2021-09-21	科德克希思公司	具有改进的活性的新颖p450-bm3变体
IT201900008808A1 (it)	2019-06-13	2020-12-13	Univ Ca Foscari	Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) *	2022-06-28	2022-09-02	北京赛诺浦生物技术有限公司	一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en) *	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
RU2312860C2 (ru)	1999-04-15	2007-12-20	Бристол-Маерс Сквибб Компани	Циклические ингибиторы протеинтирозинкиназ
GB0202873D0 (en)	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
US20050164196A1 (en) *	2002-04-17	2005-07-28	Dressman Marlene M.	Methods to predict patient responsiveness to tyrosine kinase inhibitors
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
GB0222514D0 (en)	2002-09-27	2002-11-06	Novartis Ag	Organic compounds
CN1960988B (zh)	2004-06-10	2012-01-25	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
GB0421525D0 (en)	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
MY148074A (en)	2005-05-10	2013-02-28	Novartis Ag	Pharmaceutical compositions comprising imatinib and a release retardant

2007
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 EP EP07842842A patent/EP2068938B1/fr active Active
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 CA CA002662977A patent/CA2662977A1/fr not_active Abandoned
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/fr active Application Filing
- 2007-09-20 EP EP10171365A patent/EP2251042A3/fr not_active Withdrawn
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
- 2009-12-04 HK HK09111401.1A patent/HK1133194A1/xx not_active IP Right Cessation
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
- 2011-04-07 HR HR20110250T patent/HRP20110250T1/hr unknown
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT2068938E (pt)	2011-03-23
AU2007299764A1 (en)	2008-03-27
ATE495761T1 (de)	2011-02-15
RU2009114856A (ru)	2010-10-27
JP2010504353A (ja)	2010-02-12
IL197296A (en)	2011-11-30
WO2008036792A3 (fr)	2008-11-13
CY1111356T1 (el)	2015-08-05
EP2068938A2 (fr)	2009-06-17
EP2068938B1 (fr)	2011-01-19
PL2068938T3 (pl)	2011-06-30
CL2007002725A1 (es)	2008-05-16
MA30786B1 (fr)	2009-10-01
DK2068938T3 (da)	2011-04-04
TWI398251B (zh)	2013-06-11
CA2662977A1 (fr)	2008-03-27
JP5735742B2 (ja)	2015-06-17
NZ575113A (en)	2012-03-30
BRPI0717099A2 (pt)	2013-10-15
HRP20110250T1 (hr)	2011-05-31
ZA200901220B (en)	2010-02-24
MX2009003082A (es)	2009-04-01
NO20091490L (no)	2009-06-15
US20170007605A1 (en)	2017-01-12
EP2251042A2 (fr)	2010-11-17
US20090281113A1 (en)	2009-11-12
KR20090065512A (ko)	2009-06-22
AU2007299764B2 (en)	2011-10-13
TW200822926A (en)	2008-06-01
EP2251042A3 (fr)	2012-05-02
WO2008036792A2 (fr)	2008-03-27
IL197296A0 (en)	2011-08-01
DE602007012122D1 (de)	2011-03-03
HK1133194A1 (en)	2010-03-19

Similar Documents

Publication	Publication Date	Title
TN2009000094A1 (en)	2010-08-19	Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
EA201190042A1 (ru)	2012-02-28	Имидазопиразиновые ингибиторы тирозинкиназы syk
Sánchez-Sánchez et al.	2014	NADPH oxidases as therapeutic targets in chronic myelogenous leukemia
RU2017120977A (ru)	2018-11-15	Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
WO2003103676A3 (fr)	2004-03-25	Methode destinee a traiter le cancer au moyen d'inhibiteurs des kinases
KR20210137045A (ko)	2021-11-17	수면 개선 방법
Wang et al.	2015	Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation
Lei et al.	2017	A pilot investigation of the impact of smoking cessation on biological age
SG163614A1 (en)	2010-08-30	Colon cancer related gene tom34
WO2010066891A3 (fr)	2010-08-26	Méthode de prédiction de la réponse à un traitement à l'aide d'inhibiteurs de tyrosine kinase ciblant la protéine de fusion bcr-abl chez des patients atteints de leucémie myéloïde chronique
RU2010101634A (ru)	2011-07-27	Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
BRPI0518795A2 (pt)	2008-12-09	mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
RU2020134183A (ru)	2020-12-01	Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
Ozgur-Akdemir et al.	2011	Imatinib mesylate (Gleevec) as protein-tyrosine kinase inhibitor elicits smooth muscle relaxation in isolated human prostatic tissue
Wajid et al.	2018	Early molecular response with imatinib therapy in chronic myeloid leukemia and its association with baseline white blood cell count and spleen size
EA201300410A1 (ru)	2014-01-30	Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
US20110224224A1 (en)	2011-09-15	Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate
Rodriguez et al.	2020	AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
TW200507828A (en)	2005-03-01	Method for treatment of chemotherapy-induced diarrhea
RU2483732C2 (ru)	2013-06-10	СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ
CN102526734A (zh)	2012-07-04	治疗年龄相关性听力损失的药物组合物及其应用
Chen et al.	2021	The Role of Abnormal Expression of Clock Gene DBP Mediated by Gut Microbiota Dysbiosis in Cognitive Dysfunction in ESRD and the Underlying Mechanism: PO2485
Li et al.	2024	Aurora kinase A promotes trained immunity via regulation of endogenous S-adenosylmethionine metabolism
DeLalio et al.	2021	Circadian Cycle Exaggerates Sympathoexcitatory Responses to Activation of Chemosensitive Renal Sensory Nerves: PO2486
Radich	2023	The (near) miracle of therapy in chronic myeloid leukaemia.